posted on 2024-10-16, 10:20authored byLi-Wei Kuo, Lyndsey S. Crump, Kathleen O’Neill, Michelle M. Williams, Jessica L. Christenson, Nicole S. Spoelstra, Micaela Kalani Roy, Amy Argabright, Julie A. Reisz, Angelo D’Alessandro, Meher P. Boorgula, Andrew Goodspeed, Mike Bickerdike, Benjamin G. Bitler, Jennifer K. Richer
Compound AT-0174 decreased secreted KYN in TDO2 overexpression (OE) cells.
History
ARTICLE ABSTRACT
TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity.